Status | Study |
Recruiting |
Study Name: Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms Condition: Rett Syndrome Date: 2016-05-24 Interventions: Drug: Sarizotan 2 to 10 mg per |
Recruiting |
Study Name: The Findings of MR Imaging in Rett Syndrome Condition: Rett Syndrome Date: 2016-05-03 Interventions: Other: Rett Syndrome Diagnosis of Rett Syndrome |
Recruiting |
Study Name: Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome Condition: Fragile X Syndrome Genetic Diseases Date: 2015-12-21 Interventions: Drug: Lovastatin Once per day |
Recruiting |
Study Name: Natural History of Rett Syndrome & Related Disorders Condition: Rett Syndrome MECP2 Duplication dIsorder RTT-related Condi Date: 2015-11-22 |
Recruiting |
Study Name: Biobanking of Rett Syndrome and Related Disorders Condition: Rett Syndrome MECP2 Duplication CDKL5 Date: 2015-11-22 |
Recruiting |
Study Name: Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age Condition: Hunter Syndrome Date: 2015-05-20 Interventions: Drug: Elaprase for intravenous (IV) infusion Patients enrolled in this study will receive once-weekly IV |
Not yet recruiting |
Study Name: Triac Trial II in MCT8 Patients Condition: Allan-Herndon-Dudley Syndrome Date: 2015-03-07 Interventions: Drug: Triac Triac, following a dose-escalation scheme |
Active, not recruiting |
Study Name: Triac Trial in MCT8 Patients Condition: Allan-Herndon-Dudley Syndrome Date: 2014-02-05 Interventions: Drug: Triac Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding pr |
Terminated |
Study Name: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes Condition: Fragile-X Syndrome Date: 2012-10-18 |
Terminated |
Study Name: Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay Condition: Fragile X Syndrome Date: 2012-06-07 |